Status:
COMPLETED
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Lead Sponsor:
Pfizer
Conditions:
Seizure Disorder, Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
Eligibility Criteria
Inclusion
- Must have met the inclusion criteria for preceding double-blind study
- Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion
- Cannot have absence seizures
Key Trial Info
Start Date :
October 1 1998
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT00141245
Start Date
October 1 1998
End Date
November 1 2005
Last Update
January 1 2007
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Deakin, Australian Capital Territory, Australia, 2600
2
Pfizer Investigational Site
Chatswood, New South Wales, Australia, 2067
3
Pfizer Investigational Site
Westmead, New South Wales, Australia, 2145
4
Pfizer Investigational Site
Maroochydore, Queensland, Australia, 4558